Login / Signup

Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials.

Serge A JabbourJochen SeufertAndré J ScheenClifford J BaileyCathrina KarupAnna M Langkilde
Published in: Diabetes, obesity & metabolism (2017)
The overall incidence rates of AEs and SAEs were similar in the dapagliflozin and placebo/control groups, including the incidence of hypoglycaemia, volume depletion, fractures, UTIs, amputations and DKA. Genital infections were more frequent with dapagliflozin than placebo.
Keyphrases
  • phase iii
  • clinical trial
  • risk factors
  • double blind
  • type diabetes
  • electronic health record
  • placebo controlled
  • big data
  • phase ii
  • randomized controlled trial
  • deep learning
  • study protocol